Genmab — September 2016
-
Hold da kæft et prishop http://finance.yahoo.com/q?s=TBRA%2C+&ql=0
-
-
Gilead Sciences, Inc. (NASDAQ:GILD) suggested recently it might be interested in picking up a PARP inhibitor near term, if it can find the right candidate. TESARO Inc (NASDAQ:TSRO)’s late stage asset looks to fit the criteria for a potential asset acquisition, and both the potential, and the realization of this potential, could attract buy volume in the coming months.
The data is set for presentation at the Presidential Symposium session at the European Society for Medical Oncology 8 okt
-
Looking Ahead To The Potentially Game Changing TESARO Inc (TSRO) Data
TESARO Inc (NASDAQ:TSRO) just announced that the FDA has granted Fast Track designation to its lead ovarian, fallopian tube, or primary peritoneal cancer candidate, and that on the back of the designation...
Insider Monkey (www.insidermonkey.com)
-
Scrolling through Genmab’s 15 September presentation at the BofA ML conference last week, we noticed that the pipeline slides now include an FDA breakthrough therapy designation for the Genmab-developed antibody Teprotumumab. This is the fourth BTD for a Genmab-developed drug (Dara has two, Arzerra has one already). This has gone somewhat under the radar
-
Så fik Sukkeralf sit ønskede samarbejde med BMS. Darzalex/Opdivo kombi som Gentogen annoncerede i morges kl. 08:26. Bliver specielt spændende hvad den kan udrette i lymfekræft.
-
Er det ikke første kombi studie i lymfekræft med Darzalex?
-
link?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind